Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,387 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Complement activation induces excessive T cell cytotoxicity in severe COVID-19.
Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, Kostevc T, Gäbel C, Schneider M, Streitz M, Demichev V, Gemünd I, Barone M, Tober-Lau P, Helbig ET, Hillus D, Petrov L, Stein J, Dey HP, Paclik D, Iwert C, Mülleder M, Aulakh SK, Djudjaj S, Bülow RD, Mei HE, Schulz AR, Thiel A, Hippenstiel S, Saliba AE, Eils R, Lehmann I, Mall MA, Stricker S, Röhmel J, Corman VM, Beule D, Wyler E, Landthaler M, Obermayer B, von Stillfried S, Boor P, Demir M, Wesselmann H, Suttorp N, Uhrig A, Müller-Redetzky H, Nattermann J, Kuebler WM, Meisel C, Ralser M, Schultze JL, Aschenbrenner AC, Thibeault C, Kurth F, Sander LE, Blüthgen N, Sawitzki B; PA-COVID-19 Study Group. Georg P, et al. Among authors: demir m. Cell. 2022 Feb 3;185(3):493-512.e25. doi: 10.1016/j.cell.2021.12.040. Epub 2021 Dec 28. Cell. 2022. PMID: 35032429 Free PMC article.
Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial.
Kurth F, Helbig ET, Lippert LJ, Thibeault C, Barbone G, Eckart MA, Kluge M, Puengel T, Demir M, Röhle R, Keller T, Ruwwe-Glösenkamp C, Witzenrath M, Suttorp N, von Kalle C, Sander LE, Jochum C, Tacke F. Kurth F, et al. Among authors: demir m. J Glob Antimicrob Resist. 2023 Mar;32:44-47. doi: 10.1016/j.jgar.2022.12.004. Epub 2022 Dec 23. J Glob Antimicrob Resist. 2023. PMID: 36572146 Free PMC article. Clinical Trial.
Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.
Loosen SH, Schulze-Hagen M, Vucur M, Gorgulho J, Paffenholz P, Benz F, Mohr R, Demir M, Wree A, Kuhl C, Trautwein C, Tacke F, Bruners P, Luedde T, Roderburg C. Loosen SH, et al. Among authors: demir m. JGH Open. 2021 Feb 1;5(3):356-363. doi: 10.1002/jgh3.12501. eCollection 2021 Mar. JGH Open. 2021. PMID: 33732882 Free PMC article.
Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.
Knorr J, Kaufmann B, Inzaugarat ME, Holtmann TM, Geisler L, Hundertmark J, Kohlhepp MS, Boosheri LM, Chilin-Fuentes DR, Birmingham A, Fisch KM, Schilling JD, Loosen SH, Trautwein C, Roderburg C, Demir M, Tacke F, Hoffman HM, Feldstein AE, Wree A. Knorr J, et al. Among authors: demir m. Hepatology. 2023 Jun 1;77(6):1968-1982. doi: 10.1002/hep.32776. Epub 2022 Oct 12. Hepatology. 2023. PMID: 36059147 Free PMC article.
Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.
Mohr R, Jost-Brinkmann F, Özdirik B, Lambrecht J, Hammerich L, Loosen SH, Luedde T, Demir M, Tacke F, Roderburg C. Mohr R, et al. Among authors: demir m. Front Immunol. 2021 Mar 30;12:652172. doi: 10.3389/fimmu.2021.652172. eCollection 2021. Front Immunol. 2021. PMID: 33859646 Free PMC article. Review.
1,387 results